Reading Time: 2 minutes
United Therapeutics (UTHR) is back on my radar after the surprising patent victory against Liquidia Technologies (LQDA). The biotech competitor has launched Yutrepia, a direct competitor to Tyvaso. Since its market launch in June 2025, Yutrepia has rapidly grown, achieving $170.4 million in sales in the second quarter. At the same time, Tyvaso sales decreased by 4% to $452.6 million. The ruling is not yet final, as Liquidia plans to appeal. If they lose the PH-ILD indication, the competitive pressure on Tyvaso would significantly decrease. Cantor...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
